Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2012

Costa Daniel B, Kobayashi Susumu

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib
Share to Drug Resistance, Neoplasm
Share to Fatal Outcome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to Pyrazoles

Share to Pyridines

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 22334013
DOI: 10.1097/JTO.0b013e318241daab

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.PMID 22334013Read ↗

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.Semantic proximity Read ↗

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.Semantic proximity Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataSemantic proximity Read ↗

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Semantic proximity Read ↗

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.Semantic proximity Read ↗

[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].Semantic proximity Read ↗

The battle against ALK resistance: successes and setbacksSemantic proximity Read ↗

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.Semantic proximity Read ↗

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.Semantic proximity Read ↗

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.